scholarly journals Effects of immunoregulatory drugs on human peripheral blood T lymphocytes function in vitro

2002 ◽  
Vol 10 (1) ◽  
pp. 19-23
Author(s):  
Marija Hatzistilianou ◽  
Soultana Hitoglou ◽  
Despina Gougoustamou ◽  
Alexandros Kotsis ◽  
Athanasios Kallinderes ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Lymphocyte Proliferation ◽  
Human Peripheral Blood ◽  
Tritiated Thymidine ◽  
Interleukin 2 ◽  
Peripheral Blood Lymphocytes ◽  
Dependent Manner ◽  
T Lymphocyte Subsets ◽  
Activation Antigens

BACKGROUND: The purpose of the study was to evaluate the mode of action of different immunoregulatory drugs in lymphocyte proliferation and activation METHODS: The drugs studied were prednisolone (PRED), cyclosporin A (CsA) the recombination of PRED and CsA, L-asparaginase and cytosine-arabinose (ara-C). Peripheral blood lymphocytes from normal blood donors were stimulated by phytohemagglutinin (PHA). Lymphocytes proliferation and activation were determined by tritiated thymidine ([3H]TdR) incorporation secretion of interleukin-2, level of soluble interleukin-2 receptors in the supernatant of the culture medium, and immunophenotyping analysis of T lymphocyte subsets. RESULTS: Among PRED CsA and their combination, the strongest inhibition of cell proliferation was induced by PRED while L-asparaginase and ara-C inhibited PHA stimulated T cells proliferation in concentration and time dependent manner. Among PRED, CsA and their combination, CsA induced the greatest inhibition of IL-2 production. All the immunoregulatory drugs inhibited lymphocyte proliferation and expression of activation antigens. CONCLUSION: The immunoregulatory drugs inhibit both lymphocyte proliferation and activation but in a different way.

Long-Term Follow-up of Patients with Recurrent Malignant Gliomas Treated with Adjuvant Adoptive Immunotherapy

Neurosurgery ◽  
1991 ◽  
Vol 28 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Kevin O. Lillehei ◽  
Dawn H. Mitchell ◽  
Stephen D. Johnson ◽  
Larry E. McCleary ◽  
Carol A. Kruse
Keyword(s):  
Survival Time ◽  
Adoptive Immunotherapy ◽  
Peripheral Blood ◽  
Interleukin 2 ◽  
Peripheral Blood Lymphocytes ◽  
Lak Cells ◽  
Prior Chemotherapy ◽  
Blood Lymphocytes ◽  
Significant Difference

Abstract Between August 1986 and October 1987, the Denver Brain Tumor Research Group conducted a clinical trial using autologous human recombinant interleukin-2 (rIL-2)-activated lymphocytes to treat 20 patients with recurrent high-grade gliomas. The trial involved surgical resection and/or decompression followed by intracavitary implantation of lymphokine-activated killer (LAK) cells and autologous stimulated lymphocytes (ASL) along with rIL-2 in a plasma clot. One month later, stimulated lymphocytes and rIL-2 were infused through a Rickham reservoir attached to a catheter directed into the tumor bed. The LAK cells were rIL-2-activated peripheral blood lymphocytes cultured for 4 days; the ASL were lectin- and rIL-2-activated peripheral blood lymphocytes cultured for 10 days. Of the 20 patients treated, 11 were evaluated as a group (mean age, 44 years, range, 15-61 years; mean Karnofsky rating, 69, range, 50-100; mean Decadron dose at entry, 14 mg/d. range, 0-32). The average number of lymphocytes implanted was 7.6 × 109 (range, 1.9-27.5 × 109), together with 1 to 4 × 106 U of rIL-2. To date, 10 of the 11 patients died, all from recurrent tumor growth. The median overall survival time was 63 weeks (range, 36-201; mean, 86). The median survival time after immunotherapy was 18 weeks (range, 11-151; mean, 39). No significant difference in survival after immunotherapy was found between those patients who had received previous chemotherapy and those who had not. The use of steroids or prior chemotherapy did not influence the in vitro generation of ASL or LAK cells. Prior chemotherapy did correlate, however, with diminished in vitro cytotoxicity against the natural killer-sensitive (K562) target cell by LAK cells (P < 0.05) but not that by ASL. There were no major adverse side effects. Although adoptive immunotherapy was safe and well tolerated, its therapeutic potential remains in question.

scholarly journals In vitro cytogenetic toxicity of bezafibrate in human peripheral blood lymphocytes

2017 ◽  
Vol 69 (4) ◽  
pp. 579-589 ◽  
Author(s):  
M. Topaktas ◽  
N. E. Kafkas ◽  
S. Sadighazadi ◽  
E. S. Istifli
Keyword(s):  
Peripheral Blood ◽  
Human Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Blood Lymphocytes ◽  
Human Peripheral Blood Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document